{"nctId":"NCT00553787","briefTitle":"Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions","startDateStruct":{"date":"2007-11"},"conditions":["Obesity","Type 2 Diabetes"],"count":2487,"armGroups":[{"label":"VI-0521 Top","type":"EXPERIMENTAL","interventionNames":["Drug: VI-0521"]},{"label":"VI-0521 Mid","type":"EXPERIMENTAL","interventionNames":["Drug: VI-0521"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: VI-0521"]}],"interventions":[{"name":"VI-0521","otherNames":[]},{"name":"VI-0521","otherNames":[]},{"name":"VI-0521","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed Consent\n* BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)\n* 70 years of age or less\n* Have 2 or more of the following obesity-related co-morbid conditions:\n\n  * Systolic blood pressure 140-160 mmHg (130-160 if diabetic);\n  * Diastolic blood pressure 90-100 mmHg (85-100 if diabetic);\n  * Requirement for 2 or more medications to achieve control (\\<140/90 mmHg)\n* Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to achieve control (\\<200 mg/dL)\n* At lease one of the following metabolic criteria:\n\n  * Fasting blood glucose level \\> 100 mg/dL\n  * Glucose level \\> 140 mg/dL\n  * Diagnosis of type 2 diabetes\n* Waist circumference ≥ 102 cm for men or ≥88 cm for women\n\nExclusion Criteria:\n\n* Stroke/MI/unstable cardiovascular disease within 6 months\n* Clinically significant renal, hepatic or psychiatric disease\n* Unstable thyroid disease or replacement therapy\n* Nephrolithiasis\n* Obesity of known genetic or endocrine origin\n* Participation in a formal weight loss program or lifestyle intervention\n* Glaucoma or intraocular pressure\n* Pregnancy or breastfeeding\n* Drug or Alcohol abuse\n* Smoking cessation within previous 3 months or plans to quit smoking during study\n* Eating disorders\n* Cholelithiasis within past 6 months\n* Excluded medications\n* Type 1 diabetes or use of any antidiabetic medication other than metformin\n* Previous bariatric surgery\n* Bipolar disorder or psychosis\n* Steroid hormone therapy\n* Systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg\n* Creatinine clearance \\< 60 mL/minute","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Weight Loss From Baseline to Week 56","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"0.277"},{"groupId":"OG001","value":"7.81","spread":"0.365"},{"groupId":"OG002","value":"9.84","spread":"0.275"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"62.1","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":993},"commonTop":["Upper Respiratory Tract Infection","constipation","dry mouth","paresthesia","Nasopharyngitis"]}}}